\BOOKMARK [0][-]{section*.4}{Acronyms}{}% 1
\BOOKMARK [0][-]{chapter.4}{Synthetic Lethal Analysis of Gene Expression Data}{}% 114
\BOOKMARK [1][-]{section.4.1}{Synthetic Lethal Genes in Breast Cancer}{chapter.4}% 115
\BOOKMARK [2][-]{subsection.4.1.1}{Synthetic Lethal Pathways in Breast Cancer}{section.4.1}% 116
\BOOKMARK [2][-]{subsection.4.1.2}{Expression Profiles of Synthetic Lethal Partners}{section.4.1}% 117
\BOOKMARK [3][-]{subsubsection.4.1.2.1}{Subgroup Pathway Analysis}{subsection.4.1.2}% 118
\BOOKMARK [1][-]{section.4.2}{Comparing Synthetic Lethal Gene Candidates}{chapter.4}% 119
\BOOKMARK [2][-]{subsection.4.2.1}{Primary siRNA Screen Candidates}{section.4.2}% 120
\BOOKMARK [2][-]{subsection.4.2.2}{Comparison with Correlation}{section.4.2}% 121
\BOOKMARK [2][-]{subsection.4.2.3}{Comparison with Primary Screen Viability}{section.4.2}% 122
\BOOKMARK [2][-]{subsection.4.2.4}{Comparison with Secondary siRNA Screen Validation}{section.4.2}% 123
\BOOKMARK [2][-]{subsection.4.2.5}{Comparison to Primary Screen at Pathway Level}{section.4.2}% 124
\BOOKMARK [3][-]{subsubsection.4.2.5.1}{Resampling Genes for Pathway Enrichment}{subsection.4.2.5}% 125
\BOOKMARK [2][-]{subsection.4.2.6}{Integrating Synthetic Lethal Pathways and Screens}{section.4.2}% 126
\BOOKMARK [1][-]{section.4.3}{Metagene Analysis}{chapter.4}% 127
\BOOKMARK [2][-]{subsection.4.3.1}{Pathway Expression}{section.4.3}% 128
\BOOKMARK [2][-]{subsection.4.3.2}{Somatic Mutation}{section.4.3}% 129
\BOOKMARK [2][-]{subsection.4.3.3}{Synthetic Lethal Pathway Metagenes}{section.4.3}% 130
\BOOKMARK [2][-]{subsection.4.3.4}{Synthetic Lethality in Breast Cancer}{section.4.3}% 131
\BOOKMARK [1][-]{section.4.4}{Replication in Stomach Cancer}{chapter.4}% 132
\BOOKMARK [2][-]{subsection.4.4.1}{Synthetic Lethal Genes and Pathways}{section.4.4}% 133
\BOOKMARK [2][-]{subsection.4.4.2}{Synthetic Lethal Expression Profiles}{section.4.4}% 134
\BOOKMARK [2][-]{subsection.4.4.3}{Comparison to Primary Screen}{section.4.4}% 135
\BOOKMARK [3][-]{subsubsection.4.4.3.1}{Resampling Analysis}{subsection.4.4.3}% 136
\BOOKMARK [2][-]{subsection.4.4.4}{Metagene Analysis}{section.4.4}% 137
\BOOKMARK [1][-]{section.4.5}{Global Synthetic Lethality}{chapter.4}% 138
\BOOKMARK [2][-]{subsection.4.5.1}{Hub Genes}{section.4.5}% 139
\BOOKMARK [2][-]{subsection.4.5.2}{Hub Pathways}{section.4.5}% 140
\BOOKMARK [1][-]{section.4.6}{Replication in the Cancer Cell Line Encyclopaedia}{chapter.4}% 141
\BOOKMARK [1][-]{section.4.7}{Discussion}{chapter.4}% 142
\BOOKMARK [2][-]{subsection.4.7.1}{Strengths of the SLIPT Methodology}{section.4.7}% 143
\BOOKMARK [2][-]{subsection.4.7.2}{Synthetic Lethal Pathways for E-cadherin}{section.4.7}% 144
\BOOKMARK [2][-]{subsection.4.7.3}{Replication and Validation}{section.4.7}% 145
\BOOKMARK [3][-]{subsubsection.4.7.3.1}{Integration with siRNA Screening}{subsection.4.7.3}% 146
\BOOKMARK [3][-]{subsubsection.4.7.3.2}{Replication across Tissues and Cell lines}{subsection.4.7.3}% 147
\BOOKMARK [1][-]{section.4.8}{Summary}{chapter.4}% 148
\BOOKMARK [0][-]{section*.46}{References}{}% 193
